The main objective of the Investment approach is to generate capital appreciation through investments in equities with a medium to long-term perspective.
| Alpha (1Y) | Beta (1Y) | Standard Deviation (1Y) | % of +ve Months (SI) |
|---|---|---|---|
| 16.61% | 0.31 | 11.71% | 60% |
Performance Table #
| Trailing Returns (%) | 1m return | 3m return | 6m return | 1y return | 2y return | 3y return | 5y return | 10y return | Since inception return |
|---|---|---|---|---|---|---|---|---|---|
| Kotak AMC Pharma Fund | -8.38% | -5.17% | -3.42% | 15.93% | 28.69% | 15.15% | 22.84% | - | 13.69% |
| NIFTY 50 TRI | -0.45% | -2.71% | -5.31% | 9.58% | 16.70% | 12.01% | 15.80% | - | 13.80% |
QRC Report Card *
| Strategy | Category | Fund Manager | Date of Inception | Age Of PMS | Corpus (in Cr, approx) | Benchmark | Returns SI (CAGR) | Stocks In Portfolio | Sectors In Portfolio |
|---|---|---|---|---|---|---|---|---|---|
| Kotak AMC Pharma Fund | Multi Cap | Anshul Saigal | 20 September 2016 | 8Y 4M | 25.7 | NIFTY 50 TRI | 13.69% | - | 2 |
| Portfolio Quality (Q) | Portfolio Risk (R) | Portfolio Consistency (C) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Index | Category Alpha (1Y) | Relative Alpha (1Y) |
% of +ve Months
(Fund Data) |
Alpha (1Y) | Beta (1Y) |
Standard Deviation (1Y)
(Fund Data) |
Sharpe Ratio (1Y)
(Fund Data) |
Alpha (SI) | Information Ratio (SI) | Consistency Ratio % |
| Nifty 50 | 12.07% | 9.94% | 60% | 22.01% | 0.33 | 11.71% | 2.53 | 1.93% | 0.12 | 51.00 % |
| Nifty 500 | 7.79% | 8.82% | 16.61% | 0.31 | 0.72% | 0.04 | 51.00 % | |||
| Nifty Midcap 100 | 0.73% | 11.16% | 11.89% | 0.29 | -1.67% | -0.09 | 48.00 % | |||
| Nifty Smallcap 100 | 0.03% | 10.52% | 10.55% | 0.21 | 0.89% | 0.04 | 47.00 % | |||
VIEW DETAILED QUALITY, RISK, CONSISTENCY ANALYSIS
Portfolio Holdings
| Holding | % |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD | 15.70 |
| CIPLA LTD | 12.10 |
| FORTIS HEALTHCARE LTD | 7.40 |
| SYNGENE INTERNATIONAL LTD | 6.30 |
| IPCA LABORATORIES LTD | 6.10 |
| DIVI'S LABORATORIES LTD | 5.90 |
| DR REDDY'S LABORATORIES LTD | 5.60 |
| ZYDUS LIFESCIENCES LTD | 5.20 |
| TORRENT PHARMACEUTICALS LTD | 4.10 |
| AUROBINDO PHARMA LTD | 3.80 |
| LAURUS LABS LTD | 3.60 |
| METROPOLIS HEALTHCARE LTD | 3.60 |
| HIKAL LTD | 3.50 |
| BIOCON LTD | 3.40 |
| GLAND PHARMA LTD | 3.20 |
| PFIZER LTD | 2.90 |
| INDOCO REMEDIES LTD | 2.10 |
| GLENMARK PHARMACEUTICALS LTD | 1.50 |
| AJANTA PHARMA LTD | 1.20 |
Sector Allocation
| Holding | % |
|---|---|
| PHARMA & BIOTECH | 79.80 |
| HEALTHCARE SERVICES | 17.20 |
Market Cap Allocation
| Allocations | % |
|---|---|
| Large Cap | 50.60 |
| Mid Cap | 30.60 |
| Small Cap | 17.70 |
| Cash | 1.10 |
Do Not Simply Invest, Make Informed Decisions
WISH TO MAKE INFORMED INVESTMENTS FOR LONG TERM WEALTH CREATION
Book
a call with our PMS AIF Specialists
Disclaimer
#Returns as of 31 Jan 2025. Returns up to 1 Year are absolute, above 1 Year are CAGR.
*QRC Report Card data is updated quarterly. Current data is as of Dec 24.
